https://www.oncnursingnews.com/view/nccn-recommends-lurbinectedin-for-secondline-treatment-of-relapsed-sclc
NCCN Recommends Lurbinectedin for Second-Line Treatment of Relapsed SCLC | Oncology Nursing News
Oct 6, 2026 - Lurbinectedin (Zepzelca) was added to the Clinical Practice Guidelines in Oncology by the National Comprehensive Cancer Network (NCCN) on July 7, 2020 for the...
second line treatmentoncology nursingnccnrecommendslurbinectedin
https://oncodaily.com/science/252617
Triparna Sen: Lurbinectedin sensitizes PD-L1 blockade therapy in small-cell lung cancer - OncoDaily
Mar 8, 2025 - Triparna Sen: Lurbinectedin sensitizes PD-L1 blockade therapy in small-cell lung cancer / cancer, Cell Reports Medicine, IMForte Phase 3 trial, LUPER study,
small celllung cancersenlurbinectedinblockade